Le Lézard
Classified in: Health
Subjects: RCL, CFG

Public advisory - Expanded recall: ratio-ECTOSONE (TEVA-ECTOSONE) 0.1% regular lotion and 0.05% mild lotion recalled due to an impurity that may pose health risks


OTTAWA, ON, Aug. 3, 2024 /CNW/ -

Summary

Images

ratio-Ectosone1 (CNW Group/Health Canada (HC))

ratio-Ectosone 0.1% (CNW Group/Health Canada (HC))

Affected products

Product 

DIN              

Lot           

Expiry            

Date added     

ratio-ECTOSONE (TEVA-ECTOSONE)
0.1% regular lotion, 60 mL                         

00750050

686589

686592

686652

686653

687324

687325

687517

687518

688546

688547

688825

688826

690415

690416

690417

690418

8/31/2024

8/31/2024

9/30/2024

9/30/2024

1/31/2025

1/31/2025

2/28/2025

2/28/2025

9/30/2025

9/30/2025

12/31/2025

12/31/2025

12/31/2026

1/31/2027

1/31/2027

1/31/2027

2024-08-03

ratio-ECTOSONE (TEVA-ECTOSONE)
0.05% mild lotion, 60 mL

00653209

690516

1/31/2026

2024-08-03

ratio-ECTOSONE (TEVA-ECTOSONE)
0.05% mild lotion, 60 mL

00653209

688519

06/2024

2024-06-28

Issue
UPDATE ? August 3, 2024:

Teva Canada Ltd. is expanding its recall to all lots of ratio-ECTOSONE (TEVA-ECTOSONE) 0.1% regular lotion and ratio-ECTOSONE (TEVA-ECTOSONE) 0.05% mild lotion after testing detected the same impurity, betamethasone enol aldehyde, above the accepted limit in some additional lots.

In addition, the products are being recalled because of labelling errors, including dosing instructions. The labels state "once or twice daily" when they should say "two to three times daily." Following the incorrect dosing instructions on the label may decrease the product's overall effectiveness in relieving skin conditions.

Original Advisory ? June 28, 2024: One lot of ratio-ECTOSONE (TEVA-ECTOSONE) 0.05% mild lotion recalled due to an impurity that may pose health risks

Teva Canada Ltd. is recalling one lot of ratio-ECTOSONE (TEVA-ECTOSONE) 0.05% mild lotion in 60 mL bottles. This action follows testing that detected an impurity?betamethasone enol aldehyde?above the accepted limit in the affected lot. This impurity can form due to a chemical change in the drug during storage and may pose health risks, including the possibility of adverse reactions on the skin or elsewhere in the body from being absorbed into the bloodstream. The risk may be greater in children who may absorb proportionally larger amounts of the impurity and be more susceptible to adverse reactions.

The product is a prescription corticosteroid lotion used to relieve skin inflammation and itch caused by skin conditions such as eczema, psoriasis and dermatitis. The affected lot was distributed to pharmacies in Canada between November 24, 2022 and March 22, 2023.

Health Canada is monitoring the company's recall, and its implementation of any necessary corrective and preventative actions to prevent this issue from reoccurring.

What you should do

Related links:

Également disponible en français

SOURCE Health Canada (HC)


These press releases may also interest you

at 09:15
FUJIFILM Irvine Scientific, Inc., a world leader in the development and manufacture of serum-free and chemically defined cell culture media for bioproduction and cell therapy manufacturing, today announced the development of Oceo Rover, a...

at 09:15
Newport Healthcare, the nation's leading provider of evidence-based behavioral health treatment for youth, young adults, and families, is proud to announce that Michael Roeske, PsyD, Senior Director for the Newport Healthcare Center for Research and...

at 09:15
A new report captures the critical strategies and initiatives that drive meaningful change in health equity. Leaders from the American Hospital Association, the Black Directors Health Equity Agenda and The Health...

at 09:15
Senior Market Sales® (SMS), one of the nation's leading insurance marketing organizations, announced that longtime President Jim Summers is the new CEO and that Senior Vice President, Marketing and Strategic Development John Haver now moves into the...

at 09:10
IQVIAtm , a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry, today announced that Frost & Sullivan, a leading independent research and consulting firm, has awarded IQVIA...

at 09:10
RxCell Inc. is pleased to announce the issuance of U.S. Patent 11,946,069 entitled "Method for Generating Multiple Cellular Products from Single Pluripotent Cell Source", a significant advancement in the field of regenerative medicine. This patent,...



News published on and distributed by: